Literature DB >> 30290826

Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients.

Matteo Bassetti1,2, Alessandro Russo3, Elda Righi3, Elisabetta Dolso3, Maria Merelli3, Nicola Cannarsa3, Federica D'Aurizio3, Assunta Sartor3, Francesco Curcio3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30290826      PMCID: PMC6173871          DOI: 10.1186/s13054-018-2183-x

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
Dear Editor, Biomarkers represent an essential tool for identification of patients developing infection and to determine their clinical severity. Procalcitonin (PCT) levels appeared to be correlated with the development of severe bacterial infections [1]. Thus, PCT systematic use has been proposed as part of the diagnostic tools and for monitoring treatment duration [2, 3], but not all of the potential benefits and limitations of PCT have been investigated. We retrospectively performed a case-control study analyzing all patients with positive blood cultures (BCs) in the period of January 2017 to December 2017 at a 1100-bed teaching hospital in Italy and investigating the correlation between PCT and C-reactive protein (CRP) values (± 24 h from BC collection) in pathogens causing bloodstream infections. The study flowchart is presented in Additional file 1: Figure S1. During the study period, 1296 positive BCs were retrieved; of these, 258 (19.9%) episodes were recorded in the intensive care unit (ICU) and were included in the study. Moreover, 213 patients hospitalized in ICU with negative BC were used as control. Finally, 471 ICU patients were analyzed. Clinical characteristic and outcome of patients, according to BC results, are reported in Additional file 1: Table S1. As reported in Fig. 1, PCT concentrations (in nanograms per milliliter) were 25.1 ± 19.9 in patients with Gram-negative (GN) etiology, 29.9 ± 13.2 for Enterobacteriaceae, 8.9 ± 7.5 for Gram-positive (GP), and 2.1 ± 1.8 for fungi. Finally, in Additional file 1: Figure S1, receiver operating characteristic curves showed an area under the curve of 0.7 (95% confidence interval (CI) 0.62–0.77, P < 0.001) for PCT and 0.45 (95% CI 0.37–0.54, P = 0.32) for CRP among GN isolates, 0.74 (95% CI 0.67–0.81, P <0.001) for PCT and 0.49 (95% CI 0.4–0.57, P = 0.82) for CRP among Enterobacteriaceae, 0.46 (95% CI 0.39–0.53, P = 0.38) for PCT and 0.41 (95% CI 0.33–0.48, P = 0.01) for CRP among GP isolates, and 0.64 (95% CI 0.46–0.83, P = 0.22) for PCT and 0.59 (95% CI 0.45–0.73, P = 0.43) for CRP among fungi. Finally, logistic regression analysis showed that PCT values of more than 0.5 ng/mL and more than 10 ng/mL were independently associated with BCs positive for Enterobacteriaceae.
Fig. 1

Procalcitonin (PCT) concentrations (in nanograms per milliliter) in patients with Gram-negative, Enterobacteriaceae, Gram-positive, and fungal etiologies. Abbreviation: SD standard deviation

Procalcitonin (PCT) concentrations (in nanograms per milliliter) in patients with Gram-negative, Enterobacteriaceae, Gram-positive, and fungal etiologies. Abbreviation: SD standard deviation Our data confirmed the previous observations about the role of PCT and CRP in predicting BC results in critically ill patients [4, 5]. Of interest, CRP was not able to predict BC results, whereas PCT values correlated with GN bacteremia and, among them, specifically identified Enterobacteriaceae. High PCT values (> 10 ng/mL) were independently associated with Enterobacteriaceae isolation. Even with the limitation of a single-center experience, these results might be useful to determine another role for PCT, helping physicians in the rapid identification of bacteremic ICU patients at risk of GN infection (especially Enterobacteriaceae) and driving the choice of a more appropriate empirical therapy. Figure S1. Receiver operating characteristic curves about procalcitonin (PCT) and C-reactive protein (CRP) to predict blood cultures positive for Gram-negative (A), Enterobacteriaceae (B), Gram-positive (C), and fungal (D) etiology. Table S1. Clinical characteristics and outcome of patients according to etiology of infection. COPD chronic obstructive pulmonary disease, CRP C-reactive protein, CVC central venous catheter, ICU intensive care unit, ns not significant, PCT procalcitonin, SAPS simplified acute physiology score, SD standard deviation, SSTI skin and soft tissue infection. *Gram-positive etiology versus Gram-negative etiology. #Gram-negative etiology versus fungal etiology. §Gram-positive etiology versus fungal etiology. (DOC 435 kb)
  5 in total

1.  Diagnostic and predictive values of procalcitonin in bloodstream infections for nosocomial pneumonia.

Authors:  Sheng Tao Yan; Li Chao Sun; Rui Lian; Yong Kang Tao; Hong Bo Zhang; Guoqiang Zhang
Journal:  J Crit Care       Date:  2018-01-11       Impact factor: 3.425

2.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

Authors:  Evelien de Jong; Jos A van Oers; Albertus Beishuizen; Piet Vos; Wytze J Vermeijden; Lenneke E Haas; Bert G Loef; Tom Dormans; Gertrude C van Melsen; Yvette C Kluiters; Hans Kemperman; Maarten J van den Elsen; Jeroen A Schouten; Jörn O Streefkerk; Hans G Krabbe; Hans Kieft; Georg H Kluge; Veerle C van Dam; Joost van Pelt; Laura Bormans; Martine Bokelman Otten; Auke C Reidinga; Henrik Endeman; Jos W Twisk; Ewoudt M W van de Garde; Anne Marie G A de Smet; Jozef Kesecioglu; Armand R Girbes; Maarten W Nijsten; Dylan W de Lange
Journal:  Lancet Infect Dis       Date:  2016-03-02       Impact factor: 25.071

3.  Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial.

Authors:  Carolina F Oliveira; Fernando A Botoni; Clara R A Oliveira; Camila B Silva; Helena A Pereira; José C Serufo; Vandack Nobre
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

Review 4.  Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.

Authors:  Liliana Simon; France Gauvin; Devendra K Amre; Patrick Saint-Louis; Jacques Lacroix
Journal:  Clin Infect Dis       Date:  2004-07-02       Impact factor: 9.079

5.  Diagnostic Accuracy of Procalcitonin for Predicting Blood Culture Results in Patients With Suspected Bloodstream Infection: An Observational Study of 35,343 Consecutive Patients (A STROBE-Compliant Article).

Authors:  Abderrahim Oussalah; Janina Ferrand; Pierre Filhine-Tresarrieu; Nejla Aissa; Isabelle Aimone-Gastin; Fares Namour; Matthieu Garcia; Alain Lozniewski; Jean-Louis Guéant
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  5 in total
  4 in total

1.  Cerebrospinal fluid procalcitonin predicts Gram-negative bacterial meningitis in patients with empiric antibiotic pretreatment.

Authors:  Wen Li; Fang Yuan; Xiaolong Sun; Zhihan Zhao; Yaoyao Zhang; Wen Jiang
Journal:  Crit Care       Date:  2019-01-23       Impact factor: 9.097

2.  Correction to: Procalcitonin levels in candidemia versus bacteremia: a systematic review.

Authors:  Andrea Cortegiani; Giovanni Misseri; Mariachiara Ippolito; Matteo Bassetti; Antonino Giarratano; Ignacio Martin-Loeches; Sharon Einav
Journal:  Crit Care       Date:  2019-10-11       Impact factor: 9.097

3.  Prevalence and characterization of antimicrobial resistance among gram-negative bacteria isolated from febrile hospitalized patients in central Ethiopia.

Authors:  Andre Fuchs; Torsten Feldt; Tafese Beyene Tufa; Colin R Mackenzie; Hans Martin Orth; Tobias Wienemann; Tamara Nordmann; Sileshi Abdissa; Zewdu Hurissa; Andreas Schönfeld; Matthias Bosselmann; Dieter Häussinger; Klaus Pfeffer; Tom Luedde
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-15       Impact factor: 4.887

4.  C-Reactive Protein Monitoring and Clinical Presentation of Fever as Predictive Factors of Prolonged Febrile Neutropenia and Blood Culture Positivity after Autologous Hematopoietic Stem Cell Transplantation-Single-Center Real-Life Experience.

Authors:  Daniela Carcò; Uros Markovic; Paolo Castorina; Valeria Iachelli; Tecla Pace; Paola Guardo; Gabriella Amato; Federica Galbo; Paola Scirè; Gaetano Moschetti
Journal:  J Clin Med       Date:  2022-01-09       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.